- Home
- MIRM
as 04-18-2025 12:39pm EST
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 1.9B | IPO Year: | 2019 |
| Target Price: | $58.55 | AVG Volume (30 days): | 476.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.14 - $54.23 | Next Earning Date: | 05-07-2025 |
| Revenue: | $336,888,000 | Revenue Growth: | 80.76% |
| Revenue Growth (this year): | 29.51% | Revenue Growth (next year): | 20.27% |
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Mar 18 '25 | Sell | $44.45 | 2,415 | $107,342.89 | 2,426 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Mar 15 '25 | Sell | $44.21 | 7,879 | $348,364.47 | 18,672 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Mar 15 '25 | Sell | $44.21 | 27,279 | $1,206,121.89 | 138,641 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Mar 15 '25 | Sell | $44.41 | 57,606 | $2,554,762.72 | 2,426 | |
| Heron Patrick J | MIRM | Director | Mar 14 '25 | Buy | $44.02 | 549 | $24,214.01 | 168,672 | |
| Heron Patrick J | MIRM | Director | Mar 10 '25 | Buy | $43.27 | 2,298 | $99,517.93 | 168,672 | |
| Heron Patrick J | MIRM | Director | Mar 6 '25 | Buy | $43.55 | 1,915 | $83,661.30 | 168,672 | |
| Heron Patrick J | MIRM | Director | Mar 4 '25 | Buy | $45.35 | 1,602 | $72,723.92 | 168,672 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Mar 4 '25 | Sell | $45.66 | 14,850 | $676,928.28 | 18,672 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Mar 3 '25 | Sell | $46.90 | 40,000 | $1,876,352.64 | 138,641 |
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus
Business Wire
5 days ago
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
Business Wire
9 days ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
16 days ago
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Zacks
22 days ago
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?
MT Newswires
23 days ago
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus
Business Wire
23 days ago
LIVMARLI Now Approved in Japan for ALGS and PFIC
Simply Wall St.
a month ago
Exploring 3 High Growth Tech Stocks in the US Market
Compare MIRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.